0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Bladder cancer - Epidemiology Forecast to 202
Published Date: March 2019
|
Report Code: DELV-Epid-214
Home | Market Reports | Health | Health Conditions | Cancer
Bladder cancer Epidemiology Forecast to 2028

Bladder cancer - Epidemiology Forecast to 202

Code: DELV-Epid-214
Report
March 2019
50 Pages
Delveinsight
Region: Global,
Description
Table of Content
Tables & Figures

DelveInsight's "Bladder cancer  - Epidemiology Forecast, 2028” report provides a comprehensive analysis of the Bladder cancer  epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered
United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

 Study Period: 2016-2028

Bladder cancer  Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Bladder cancer  in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Bladder cancer  outlook. It also includes the explanation of changing trends of epidemiology outlining the Bladder cancer  scenario.

Bladder cancer  Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Bladder cancer  thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
• The report covers detailed overview of Bladder cancer  explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Bladder cancer  Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in Bladder cancer

Key assessments
• Patient Segmentation in Bladder cancer
• Bladder cancer  Risk & Burden
• Factors driving growth in a specific Bladder cancer  patient population

1.Report Introduction
2. Bladder cancer Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Bladder cancer in 2016
2.2. Patient Share Distribution of Bladder cancer in 2028
3. Disease Background and Overview: Bladder cancer
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Bladder cancer in 7MM
4.3. Total Prevalent/ Incident Patient Population of Bladder cancer in 7MM – By Countries
5. Epidemiology of Bladder cancer by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Bladder cancer
5.1.3. Sub-Type Specific cases of the Bladder cancer *
5.1.4. Sex- Specific Cases of the Bladder cancer*
5.1.5. Diagnosed Cases of the Bladder cancer
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Bladder cancer
5.4.3. Sub-Type Specific cases of the Bladder cancer*
5.4.4. Sex- Specific Cases of the Bladder cancer*
5.4.5. Diagnosed Cases of the Bladder cancer
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Bladder cancer
5.5.3. Sub-Type Specific cases of the Bladder cancer*
5.5.4. Sex- Specific Cases of the Bladder cancer*
5.5.5. Diagnosed Cases of the Bladder cancer
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Bladder cancer
5.6.3. Sub-Type Specific cases of the Bladder cancer*
5.6.4. Sex- Specific Cases of the Bladder cancer*
5.6.5. Diagnosed Cases of the Bladder cancer
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Bladder cancer
5.7.3. Sub-Type Specific cases of the Bladder cancer*
5.7.4. Sex- Specific Cases of the Bladder cancer*
5.7.5. Diagnosed Cases of the Bladder cancer
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Bladder cancer
5.8.3. Sub-Type Specific cases of the Bladder cancer*
5.8.4. Sex- Specific Cases of the Bladder cancer*
5.8.5. Diagnosed Cases of the Bladder cancer
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Bladder cancer
5.9.3. Sub-Type Specific cases of the Bladder cancer*
5.9.4. Sex- Specific Cases of the Bladder cancer*
5.9.5. Diagnosed Cases of the Bladder cancer
6. Unmet Needs of the Bladder cancer
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific

List of Table:

Table 1: Total Prevalent/Incident Cases of the Bladder cancer in 7MM
Table 2: Total Prevalent/Incident Cases of the Bladder cancer in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Bladder cancer in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Bladder cancer in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Bladder cancer in United States (2016-2028)*
Table 6: Diagnosed Cases of the Bladder cancer in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Bladder cancer in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Bladder cancer in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Bladder cancer in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Bladder cancer in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Bladder cancer in France (2016-2028)
Table 12: Sub-Type Specific cases of the Bladder cancer in France (2016-2028) *
Table 13: Sex- Specific Cases of the Bladder cancer in France (2016-2028) *
Table 14: Diagnosed Cases of the Bladder cancer in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Bladder cancer in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Bladder cancer in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Bladder cancer in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Bladder cancer in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Bladder cancer in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Bladder cancer in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Bladder cancer in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Bladder cancer in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Bladder cancer in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Bladder cancer in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Bladder cancer in UK (2016-2028) *
Table 26: Diagnosed Cases of the Bladder cancer in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Bladder cancer in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Bladder cancer in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Bladder cancer in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Bladder cancer in Japan (2016-2028)

List of Figure:

Figure 1: Total Prevalent/Incident Cases of the Bladder cancer in 7MM
Figure 2: Total Prevalent/Incident Cases of the Bladder cancer in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Bladder cancer in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Bladder cancer in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Bladder cancer in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Bladder cancer in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Bladder cancer in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Bladder cancer in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Bladder cancer in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Bladder cancer in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Bladder cancer in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Bladder cancer in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Bladder cancer in France (2016-2028) *
Figure 14: Diagnosed Cases of the Bladder cancer in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Bladder cancer in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Bladder cancer in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Bladder cancer in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Bladder cancer in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Bladder cancer in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Bladder cancer in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Bladder cancer in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Bladder cancer in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Bladder cancer in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Bladder cancer in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Bladder cancer in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Bladder cancer in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Bladder cancer in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Bladder cancer in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Bladder cancer in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Bladder cancer in Japan (2016-2028

SELECT A FORMAT
Added to Cart

Electronic (PDF)
$3250
This license allows only one user to access the PDF.

Electronic (PDF)
$6500
This license allows all the users of an enterprise residing in one location to access the PDF

Electronic (PDF)
$9750
This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Lukasiewicz Research Network

RELATED REPORTS

Global and Japan Dasatinib Drugs Market Insights Forecast to 2027
Global and Japan Dasatinib Drugs Market Insights, Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-26C6576
Sun Sep 05 00:00:00 UTC 2021

Add to Cart

Global and Japan Acute Lymphocytic Lymphoblastic Leukemia Treatment Market Size Status and Forecast 2021 2027
Global and Japan Acute Lymphocytic/Lymphoblastic Leukemia Treatment Market Size, Status and Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-11I6837
Sun Sep 05 00:00:00 UTC 2021

Add to Cart

Global and United States Acute Lymphoblastic Leukemia Therapeutics Market Size Status and Forecast 2021 2027
Global and United States Acute Lymphoblastic Leukemia Therapeutics Market Size, Status and Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-5D6786
Sun Sep 05 00:00:00 UTC 2021

Add to Cart

Global and United States Acute Lymphoblastic Leukemia Treatment Market Size Status and Forecast 2021 2027
Global and United States Acute Lymphoblastic Leukemia Treatment Market Size, Status and Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-5J6785
Sun Sep 05 00:00:00 UTC 2021

Add to Cart